| dc.creator |
Onal, Emine Meltem |
|
| dc.creator |
Sag, Alan Alper |
|
| dc.creator |
Sal, Oguzhan |
|
| dc.creator |
AFŞAR, Barış |
|
| dc.creator |
Yerlikaya, Aslihan |
|
| dc.creator |
Kanbay, Mehmet |
|
| dc.date |
2016-12-31T21:00:00Z |
|
| dc.date.accessioned |
2020-10-06T10:31:55Z |
|
| dc.date.available |
2020-10-06T10:31:55Z |
|
| dc.identifier |
70afafaa-4050-4255-8fc9-91fa03973ab1 |
|
| dc.identifier |
10.1080/10641963.2016.1246565 |
|
| dc.identifier |
https://avesis.sdu.edu.tr/publication/details/70afafaa-4050-4255-8fc9-91fa03973ab1/oai |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/63154 |
|
| dc.description |
Organ crosstalk pathways represent the next frontier for target-mining in molecular medicine for existing syndromes. Pulmonary hypertension and resistant essential hypertension are syndromes that have been proven elusive in etiology, and frequently refractory to first-line management. Underlying crosstalk mechanisms, not yet considered in these treatments, may hinder outcomes or unlock novel treatments. This review focuses systematically on erythropoietin, a synthesizable molecule, as a mediator of brain-kidney crosstalk. Insights gained from this review will be applied to cardiovascular diseases in a clinician-directed fashion. |
|
| dc.language |
eng |
|
| dc.rights |
info:eu-repo/semantics/closedAccess |
|
| dc.title |
Erythropoietin mediates brain-vascular-kidney crosstalk and may be a treatment target for pulmonary and resistant essential hypertension |
|
| dc.type |
info:eu-repo/semantics/article |
|